AI Analysis

Generated: 1 week ago. (Likely Outdated!)

Sopharma AD (SPH.WA) is a leading pharmaceutical company based in Bulgaria, with a significant presence across Eastern and Southeastern Europe. The company's business model is built on two main pillars: making medicines and distributing a wide range of health-related products.

The Business Model (How They Make Money)

Sopharma makes money primarily by developing, manufacturing, and selling a variety of pharmaceutical products. These include a broad range of generic medicines (which are cost-effective versions of branded drugs), herbal-based medicines, food supplements, veterinary products, medical devices, and even cosmetic products like plasters and bandages. Some of their well-known brands include Carsil, Tempalgin, Tabex, Tribestan, Broncholytin, and Analgin. The actual production of these goods mainly happens in Bulgaria through Sopharma AD itself, and in Serbia and Ukraine through its subsidiaries.

Beyond manufacturing, Sopharma also has a strong distribution network. They act as a wholesaler for pharmaceuticals, medical supplies, vitamins, and other health products. This distribution arm, largely managed by "Sopharma Trading," serves markets in Bulgaria, Serbia, Russia, Ukraine, Kazakhstan, Poland, and Belarus. The company also has smaller operations in pharmacy retail and real estate leasing.

Sopharma operates in approximately 41 countries, with key markets including Bulgaria, Russia, Ukraine, Kazakhstan, and Poland. A significant portion of their growth comes from selling products internationally; for instance, in early 2026, a 33% increase in exports was a major driver of their overall sales growth. For the period from the beginning of 2026 through the end of September, the company saw a 39% increase in total sales compared to the same period in the previous year, with export sales growing by an impressive 62%.

In 2025, Sopharma Group reported consolidated revenues of BGN 2,609,827 thousand (approximately 2.61 billion Bulgarian Leva).

The Metrics That Matter Most

For Sopharma, a company involved in both manufacturing and distributing health products across multiple countries, here are the most important numbers to watch:

  1. Revenue: This number tells you the total amount of money Sopharma brings in from selling its products and services. For a company like Sopharma that is focused on expanding its reach and product portfolio, consistent revenue growth shows that more people are buying their medicines and using their distribution services. In 2025, Sopharma Group's consolidated revenue was BGN 2,609,827 thousand. The company also reported strong sales growth in 2026, with a 39% increase in sales for the first nine months compared to the same period in 2025.
  2. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): Think of EBITDA as a way to see how much cash the company's core business operations are generating before accounting for things like interest payments on loans, taxes, and the cost of wear and tear on its equipment and buildings. For a company with manufacturing facilities and a wide distribution network, EBITDA helps you understand the true profitability of its day-to-day operations, without the noise of financial or accounting decisions. Sopharma Group's consolidated EBITDA for 2025 was BGN 219,181 thousand.
  3. Shares Outstanding: This simply tells you the total number of company shares that are currently owned by investors. It's important because many financial calculations, like earnings per share or dividends per share, are based on this number. Knowing the shares outstanding helps you understand how much of the company each share represents. As of the end of 2025, Sopharma AD had 539,157,603 shares outstanding.
  4. Dividends: This is the portion of the company's profits that it pays out to its shareholders. For many investors, especially those looking for regular income, dividends are a key indicator of a company's financial health and its commitment to returning value to its owners. Sopharma approved a gross dividend of EUR 0.052 per share for the year 2025.

How to Value This Company

The most relevant way to figure out if Sopharma's stock is cheap or expensive, given its business model, is by looking at its EV/EBITDA (Enterprise Value to EBITDA).

Here's why: Sopharma is a company with significant physical assets (like manufacturing plants) and a broad distribution network, which often involves debt to fund operations and expansion. EV/EBITDA helps you compare the total value of the company (its "Enterprise Value," which includes both its stock market value and its net debt) against its core operational earnings (EBITDA).

In simple terms, it tells you how many years of operational earnings it would take to "buy" the entire company, including its debt. It's a great tool for comparing Sopharma to other pharmaceutical manufacturers and distributors, especially those that might have different levels of debt or tax situations. A lower EV/EBITDA ratio might suggest the company is undervalued compared to its operational performance, while a higher ratio could mean it's considered more expensive.

鈿狅笍 Disclaimer: This analysis is generated by AI. stockpicker.tech is not responsible for any mistakes, inaccuracies, or hallucinations. This is for educational purposes only and does not constitute financial advice. Users should always double-check the information and conduct their own research before making investment decisions.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sopharma AD

PLN 13.15 +$0.60 (+4.78%)
WSE 路 18 Nov 2026 15:49 UTC
Previous Close
PLN 13.45
Day Range
PLN 12.80PLN 13.15
Year Range
PLN 6.04PLN 15.30
Market Cap
7.08B
AVG Volume
730
Trailing/Forward PE
31.11/-
PEG ratio
-1.08
Dividend Yield
3.99%
Next Earnings Date
2026-12-02
Primary Exchange
Warsaw Stock ExchangePL
Revenue (BGN) 路 TTM
01B2B3B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SPH.WA Revenue (BGN) by quarter, trailing twelve months
PeriodRevenue (BGN)
26 Q22.73B
26 Q12.66B
25 Q42.61B
25 Q32.5B
25 Q22.4B
25 Q12.26B
24 Q42.13B
24 Q32.04B
24 Q21.96B
24 Q11.92B
Net Income (BGN) 路 TTM
050M100M150M200M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SPH.WA Net Income (BGN) by quarter, trailing twelve months
PeriodNet Income (BGN)
26 Q2161.52M
26 Q1155.2M
25 Q4133.52M
25 Q3122.65M
25 Q2100.86M
25 Q186.93M
24 Q476.31M
24 Q382.68M
24 Q278.37M
24 Q193.43M
Operating Income (BGN) 路 TTM
050M100M150M200M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SPH.WA Operating Income (BGN) by quarter, trailing twelve months
PeriodOperating Income (BGN)
26 Q2179.75M
26 Q1169.26M
25 Q4145.87M
25 Q3128.86M
25 Q2103.6M
25 Q190.51M
24 Q481.76M
24 Q385.8M
24 Q283.47M
24 Q197.43M
EBITDA 路 TTM
Cash Flows 路 TTM
EPS 路 TTM
Expenses 路 TTM
Cash & Debt 路 TTM
Debt ratios 路 TTM
Margins 路 TTM
Return on Capital 路 TTM
Shares Outstanding 路 TTM
Dividends (BGN) 路 TTM
Employee Count
Book Value Per Share 路 TTM
Total Assets 路 TTM
PE Ratio
Free Cash Flow Yield
Price to Sales
EV/EBITDA
Price/Operating Cashflow
Price to Book

Earnings: SPH.WA

Estimate against actual revenue and earnings per share, the beat and miss record of recent reports, and how the price moved around each one. Next report: 2 Dec 2026.

Sopharma AD
SPH.WA
Stockpicker

Video analysis: SPH.WA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SPH.WA

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.